These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18695371)

  • 21. Drotrecogin alfa: a role in emergency department treatment of severe sepsis?
    McLeay AM
    Emerg Med Australas; 2004 Aug; 16(4):324-35. PubMed ID: 15283720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bleeding complications with Drotrecogin alfa activated (Xigris): a retrospective review of 31 operative and 68 non-operative patients with severe sepsis.
    Taylor BJ; Lee SJ; Waxman K
    Am Surg; 2008 Oct; 74(10):898-901. PubMed ID: 18942609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of drotrecogin alfa (activated) in severe sepsis during acute pancreatitis - two case studies.
    Machała W; Wachowicz N; Komorowska A; Gaszyński W
    Med Sci Monit; 2004 Jul; 10(7):CS31-6. PubMed ID: 15232511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What is the role of recombinant activated protein C in the management of sepsis?
    Alvarado J; Castro R
    Medwave; 2016 Dec; 16(Suppl5):e6801. PubMed ID: 28032853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety.
    Laterre PF; Nelson DR; Macias W; Abraham E; Sashegyi A; Williams MD; Levy M; Levi M; Utterback B; Vincent JL
    J Crit Care; 2007 Jun; 22(2):142-52. PubMed ID: 17548026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Severe sepsis and therapy with activated protein C.
    Parrillo JE
    N Engl J Med; 2005 Sep; 353(13):1398-400. PubMed ID: 16192486
    [No Abstract]   [Full Text] [Related]  

  • 27. Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial.
    Eichacker PQ; Danner RL; Suffredini AF; Cui X; Natanson C
    Crit Care Med; 2005 Oct; 33(10):2426-8. PubMed ID: 16215410
    [No Abstract]   [Full Text] [Related]  

  • 28. Activated protein C for severe sepsis.
    Ely EW; Bernard GR; Vincent JL
    N Engl J Med; 2002 Sep; 347(13):1035-6. PubMed ID: 12324564
    [No Abstract]   [Full Text] [Related]  

  • 29. Drotrecogin alfa (activated) in the treatment of severe sepsis.
    Vincent JL
    Expert Rev Anti Infect Ther; 2006 Aug; 4(4):537-47. PubMed ID: 17009934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of drotrecogin alfa (activated) in older patients with severe sepsis.
    Alexander SL; Ernst FR
    Pharmacotherapy; 2006 Apr; 26(4):533-8. PubMed ID: 16553513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant human activated protein C for the treatment of severe sepsis: is there a role in pediatrics?
    Giroir BP
    Curr Opin Pediatr; 2003 Feb; 15(1):92-6. PubMed ID: 12544278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Xigris--activated protein C].
    Tønnesen EK
    Ugeskr Laeger; 2004 Mar; 166(11):1002-4. PubMed ID: 15049235
    [No Abstract]   [Full Text] [Related]  

  • 33. Substantiating the concerns about recombinant human activated protein C use in sepsis.
    Deans KJ; Minneci PC; Banks SM; Natanson C; Eichacker PQ
    Crit Care Med; 2004 Dec; 32(12):2542-3. PubMed ID: 15599164
    [No Abstract]   [Full Text] [Related]  

  • 34. Recombinant human-activated protein C (rhAPC) in childhood sepsis.
    Frassica JJ; Vinagre YM; Maas B
    J Intensive Care Med; 2004; 19(1):56-7. PubMed ID: 15035756
    [No Abstract]   [Full Text] [Related]  

  • 35. Recombinant human activated protein C for severe sepsis.
    Kapur S; Kupfer Y; Tessler S
    N Engl J Med; 2001 Jul; 345(3):219-20; author reply 220-1. PubMed ID: 11463021
    [No Abstract]   [Full Text] [Related]  

  • 36. Safety of drotrecogin alfa (activated) in surgical patients with severe sepsis.
    Fry DE; Beilman G; Johnson S; Williams MD; Rodman G; Booth FV; Bates BM; McCollam JS; Lowry SF;
    Surg Infect (Larchmt); 2004; 5(3):253-9. PubMed ID: 15684796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activated protein C in sepsis: emerging insights regarding its mechanism of action and clinical effectiveness.
    Haley M; Cui X; Minneci PC; Deans KJ; Natanson C; Eichacker PQ
    Curr Opin Infect Dis; 2004 Jun; 17(3):205-11. PubMed ID: 15166822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of efficacy and safety of drotrecogin alfa (activated) in surgical patients, using an international integrated database.
    de Pont AC; Bakx R; Boermeester MA; Schultz MJ
    Surgery; 2007 Jun; 141(6):828-9. PubMed ID: 17560262
    [No Abstract]   [Full Text] [Related]  

  • 39. [Exogenous activated protein C in severe sepsis].
    Mamontova OA; Protsenko DN; Eliutin DV; Kirienko PN; Gel'fand BR
    Anesteziol Reanimatol; 2005; (3):42-5. PubMed ID: 16076046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of sepsis with activated protein C.
    Hinds CJ
    BMJ; 2001 Oct; 323(7318):881-2. PubMed ID: 11668121
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.